Skip to main content

Advertisement

SpringerLink
Log in

Renal dysfunction in HIV-1-infected patients

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Improved therapy directed against opportunistic infection and HIV-1 itself has resulted in greatly enhanced patient survival in the past decade among patients infected with HIV-1. Since patients are living longer, HIV-1 infection is associated with a rising burden of kidney disease. Approximately 14% of black patients and 6% of white patients dying with HIV-1 infection in 1999 in the United States had renal disease. Overall, 10% of patients dying with HIV-1 infection had renal failure. The most common glomerular diseases are focal segmental glomerulosclerosis and immune complex glomerulonephritis. Appropriate therapy for focal segmental glomerulosclerosis includes effective antiretroviral therapy and angiotensin antagonist medication. Drug toxicity is also common, often manifesting as electrolyte abnormalities, acute renal failure, interstitial nephritis, or nephrolithiasis. In particular, indinavir is associated with crystalluria, nephrolithiasis, interstitial nephritis, and lower urinary tract inflammation. Appropriate screening for renal disease and appropriate intervention will likely reduce the morbidity and mortality associated with progressive renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Selik RM, Byers RH Jr, Dworkin MS: Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002, 29:378–387. While total numbers of HIV-associated deaths have fallen over the past decade, the percentage of death certificates that mention renal disease has risen and is approximately twofold greater in black patients compared with white patients.

    PubMed  Google Scholar 

  2. Klotman PE: HIV-associated nephropathy. Kidney Int 1999, 56:1161–1176.

    Article  PubMed  CAS  Google Scholar 

  3. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461–470.

    PubMed  CAS  Google Scholar 

  4. Mouratoff JG, Tokumoto J, Olson JL, et al.: Acute renal failure with interstitial nephritis in a patient with AIDS. Am J Kidney Dis 2000, 35:557–561.

    PubMed  CAS  Google Scholar 

  5. Peraldi MN, Maslo C, Akposso K, et al.: Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Nephrol Dial Transplant 1999, 14:1578–1585.

    Article  PubMed  CAS  Google Scholar 

  6. Jayasekara D, Aweeka FT, Rodriguez R, et al.: Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr 1999, 21:384–395.

    Article  PubMed  CAS  Google Scholar 

  7. Praditpornsilpa K, Napathorn S, Yenrudi S, et al.: Renal pathology and HIV infection in Thailand. Am J Kidney Dis 1999, 33:282–286.

    PubMed  CAS  Google Scholar 

  8. Monga G, Mazzucco G, Boldorini R, et al.: Renal changes in patients with acquired immunodeficiency syndrome: a postmortem study on an unselected population in northwestern Italy. Mod Pathol 1997, 10:159–167.

    PubMed  CAS  Google Scholar 

  9. Hailemariam S, Walder M, Burger HR, et al.: Renal pathology and premortem clinical presentation of Caucasian patients with AIDS: an autopsy study from the era prior to antiretroviral therapy. Swiss Med Wkly 2001, 131:412–417.

    PubMed  CAS  Google Scholar 

  10. Shahinian V, Rajaraman S, Borucki M, et al.: Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000, 35:884–888. These authors reviewed autopsied kidneys from HIV-1-infected patients, and found that 12% of black patients had FSGS, which provides an estimate of lifetime prevalence.

    PubMed  CAS  Google Scholar 

  11. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al.: Idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:702–706.

    Article  PubMed  CAS  Google Scholar 

  12. Riser BL, Cortes P, Yee J, et al.: Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 1998, 9:827–836.

    PubMed  CAS  Google Scholar 

  13. The Sixth Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure. http://www.nhlbi.nih.gov/guidelines/hypertension/ jncintro.htm.

  14. Lewis EJ, Hunsicker LG, Bain RP, et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  15. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  16. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  17. Kopp JB, Winkler CA: HIV-associated nephropathy in African Americans. J Am Soc Nephrol 2002, In press.

  18. Freedman BI, Soucie JM, Stone SM, et al.: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999, 34:254–258.

    PubMed  CAS  Google Scholar 

  19. Poli A, Abramo F, Taccini E, et al.: Renal involvement in feline immunodeficiency virus infection: a clinicopathologic study. Nephron 1993, 64:282–288.

    PubMed  CAS  Google Scholar 

  20. Alpers CE, Tsai C-C, Hudkins KL, et al.: Focal segmental glomerulosclerosis in primates infected with a simian immunodeficiency virus. AIDS Res Hum Retrovir 1997, 13:413–424.

    PubMed  CAS  Google Scholar 

  21. Bauer FA, Wear DJ, Angritt P, et al.: Mycoplasma fermentans (incognitus strain) infection in the kidneys of patients with acquired immunodeficiency syndrome and associated nephropathy: a light microscopic, immunohistochemical, and ultrastructural study. Hum Pathol 1991, 22:63–69.

    Article  PubMed  CAS  Google Scholar 

  22. Li R-M, Branton MH, Tanawattanacharoen S, et al.: Molecularidentification of SV40 infection in human subjects and possibleassociation with kidney disease. J Am Soc Nephrol 2002, In Press.

  23. Cohen AH, Sun NCJ, Shapshak P, et al.: Demonstration of human immunodeficiency virus in renal epithelium in HIVassociated nephropathy. Mod Pathol 1989, 2:125–128.

    PubMed  CAS  Google Scholar 

  24. Bruggeman LA, Ross MD, Tanji N, et al.: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000, 11:2079–2087. This landmark study demonstrates HIV-1 RNA and DNA in glomerular epithelial cells and tubular epithelial cells in patients with HIVassociated FSGS.

    PubMed  CAS  Google Scholar 

  25. Winston JA, Bruggeman LA, Ross MD, et al.: Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001, 344:1979–1984. This case report demonstrates that the institution of HAART was associated with improved renal function but no change in renal HIV-1 RNA and DNA, suggesting that the kidney may be a sanctuary for HIV-1 replication.

    Article  PubMed  CAS  Google Scholar 

  26. Marras D, Bruggeman LA, Gao F, et al.: Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002, 8:522–526.

    Article  PubMed  CAS  Google Scholar 

  27. Conaldi PG, Biancone L, Bottelli A, et al.: HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest 1998, 102:2041–2049. This paper demonstrates HIV-1 infection of tubular epithelial cells.

    PubMed  CAS  Google Scholar 

  28. Ray PE, Liu XH, Henry D, et al.: Infection of human primary renal epithelial cells with HIV-1 from children with HIVassociated nephropathy. Kidney Int 1998, 53:1217–1229. This paper also demonstrates HIV-1 infection of tubular epithelial cells.

    Article  PubMed  CAS  Google Scholar 

  29. Conaldi PG, Bottelli A, Wade-Evans A, et al.: HIV-persistent infection and cytokine induction in mesangial cells: a potential mechanism for HIV-associated glomerulosclerosis. AIDS 2000, 14:2045–2047.

    Article  PubMed  CAS  Google Scholar 

  30. Alpers C, McClure J, Burstein SL: Human mesangial cells are resistant to productive infection by multiple strains of human immunodeficiency virus types 1 and 2. Am J Kidney Dis 1992, 19:126–130.

    PubMed  CAS  Google Scholar 

  31. Green DF, Resnick L, Bourgoignie JJ: HIV infects endothelial and mesangial but not epithelial cells. Kidney Int 1992, 41:956–960.

    PubMed  CAS  Google Scholar 

  32. Tokizawa S, Shimizu N, Hui-Yu L, et al.: Infection of mesangial cells with HIV and SIV: identification of GPR1 as a coreceptor. Kidney Int 2000, 58:607–617. Mesangial cell infection is dependent upon the GPR1 coreceptor.

    Article  PubMed  CAS  Google Scholar 

  33. Eitner F, Cui Y, Hudkins KL, et al.: Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease. J Am Soc Nephrol 2000, 11:856–867.

    PubMed  CAS  Google Scholar 

  34. Huber TB, Reinhardt HC, Exner M, et al.: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002, 168:6244–252.

    PubMed  CAS  Google Scholar 

  35. Singhal PC, Sagar S, Chandra D, et al.: Human immunodeficiency virus-1 gp120 and gp160 envelope proteins modulate mesangial cell gelatinolytic activity. Am J Pathol 1995, 147:25–32.

    PubMed  CAS  Google Scholar 

  36. Yamamoto T, Noble NA, Miller DE, et al.: Increased levels of transforming growth factor-beta in HIV-associated nephropathy. Kidney Int 1999, 55:579–592.

    Article  PubMed  CAS  Google Scholar 

  37. Husain M, Gusella GL, Klotman ME, et al.: HIV-1 nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002, 13:1806–1815.

    Article  PubMed  CAS  Google Scholar 

  38. Dickie P, Felser M, Eckhaus M, et al.: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991, 185:109–119.

    Article  PubMed  CAS  Google Scholar 

  39. Kopp JB, Klotman ME, Adler SH, et al.: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for HIV-1 genes. Proc Natl Acad Sci U S A 1992, 89:1577–1581.

    Article  PubMed  CAS  Google Scholar 

  40. Kajiyama W, Kopp JB, Marinos NJ, et al.: Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 2000, 58:1148–1159. The HIV-1 genes env, tat, rev, vif, vpr, and vpu are sufficient to induce FSGS in transgenic mice.

    Article  PubMed  CAS  Google Scholar 

  41. Reid W, Sadowska M, Denaro F, et al.: An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 2001, 98:9271–276.

    Article  PubMed  CAS  Google Scholar 

  42. Bruggeman LA, Dikman S, Meng C, et al.: Nephropathy in human immundeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997, 100:84–92.

    Article  PubMed  CAS  Google Scholar 

  43. Kimmel PL, Mishkin GJ, Umana WO: Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996, 28:202–208.

    PubMed  CAS  Google Scholar 

  44. Burns GC, Paul SK, Toth IR, et al.: Effect of angiotensinconverting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997, 8:1140–1146.

    PubMed  CAS  Google Scholar 

  45. Bird JE, Durham SK, Giancarli MR, et al.: Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol 1998, 9:1441–1447.

    PubMed  CAS  Google Scholar 

  46. Smith MC, Pawar R, Carey JT, et al.: Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 1994, 97:145–151.

    Article  PubMed  CAS  Google Scholar 

  47. Eustace JA, Nuermberger E, Choi M, et al.: Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000, 58:1253–1260.

    Article  PubMed  CAS  Google Scholar 

  48. Ifudu O, Rao TKS, Tan CC, et al.: Zidovudine improves prognosis in HIV-associated nephropathy [Abstract]. J Am Soc Nephrol 1993, 4:277.

    Google Scholar 

  49. Wali RK, Drachenberg CI, Papadimitriou JC, et al.: HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998, 352:783–784. This case report describes a patient who experienced a remarkable reversal of ESRD and regression of FSGS after the institution of HAART.

    Article  PubMed  CAS  Google Scholar 

  50. Gadallah MF, el-Shahawy MA, Campese VM, et al.: Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 1996, 16:446–450.

    Article  PubMed  CAS  Google Scholar 

  51. Segerer S, Eitner F, Cui Y, et al.: Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques. J Am Soc Nephrol 2002, 13:370–378.

    PubMed  Google Scholar 

  52. Maslo C, Peraldi MN, Desenclos JC, et al.: Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997, 24:350–355.

    PubMed  CAS  Google Scholar 

  53. Balani SK, Arison BH, Mathai L, et al.: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995, 23:266–270.

    PubMed  CAS  Google Scholar 

  54. Dieleman JP, Salahuddin S, Hsu YS, et al.: Indinavir crystallization around the loop of Henle: experimental evidence. J Acquir Immune Defic Syndr 2001, 28:9–13.

    PubMed  CAS  Google Scholar 

  55. Martinez E, Leguizamon M, Mallolas J, et al.: Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin Infect Dis 1999, 29:422–425.

    PubMed  CAS  Google Scholar 

  56. Kohan AD, Armenakas NA, Fracchia JA: Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 1999, 161:1765–1768.

    Article  PubMed  CAS  Google Scholar 

  57. Kopp JB, Miller KD, Mican JA, et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119–125. Indinavir therapy is associated with highly characteristic crystals in urine, and in addition to nephrolithiasis, indinavir is associated with dysuria and urinary obstruction.

    PubMed  CAS  Google Scholar 

  58. Gagnon RF, Tecimer SN, Watters AK, et al.: Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000, 36:507–515. Indinavir-treated patients had monthly urinalysis over a period of 1 year. Sixty-seven percent of patients manifested indinavir crystalluria on at least one urinalysis, from which one can infer that the presence of crystalluria is unlikely to be a useful predictor of urologic complications.

    PubMed  CAS  Google Scholar 

  59. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al.: Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999, 161:1082–1084.

    Article  PubMed  CAS  Google Scholar 

  60. Brodie SB, Keller MJ, Ewenstein BM, et al.: Variation in incidence of indinavir-associated nephrolithiasis among HIVpositive patients. AIDS 1998, 12:2433–2437. These authors report a high cumulative incidence (22%) of stones in patients receiving indinavir, and found an association with hepatitis Cinfection.

    Article  PubMed  CAS  Google Scholar 

  61. Saltel E, Angel JB, Futter NG, et al.: Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000, 164:1895–1897.

    Article  PubMed  CAS  Google Scholar 

  62. Herman JS, Ives NJ, Nelson M, et al.: Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001, 48:355–360. This study and the one by Dieleman et al. [63••] provide very similar estimates of the incidence of urologic complications: 6.7 and 8.3 per 100 years of drug exposure.

    Article  PubMed  CAS  Google Scholar 

  63. Dieleman JP, Sturkenboom MC, Jambroes M, et al.: Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate: The ATHENA Cohort. Arch Intern Med 2002, 162:1493–501. This study and the one by Herman et al. [62••] provide very similar estimates of the incidence of urologic complications: 6.7 and 8.3 per 100 years of drug exposure.

    Article  PubMed  Google Scholar 

  64. Berns JS, Cohen RM, Silverman M, et al.: Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997, 30:558–560.

    PubMed  CAS  Google Scholar 

  65. Malavaud B, Dinh B, Bonnet E, et al.: Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000, 5:3–5.

    PubMed  CAS  Google Scholar 

  66. Dieleman JP, Gyssens IC, van der Ende ME, et al.: Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473–478.

    Article  PubMed  CAS  Google Scholar 

  67. Schwartz BF, Schenkman N, Armenakas NA, et al.: Imaging characteristics of indinavir calculi. J Urol 1999, 161:1085–1087.

    Article  PubMed  CAS  Google Scholar 

  68. Dieleman JP, van der Feltz M, Bangma CH, et al.: Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection 2001, 29:232–233.

    Article  PubMed  CAS  Google Scholar 

  69. Gentle DL, Stoller ML, Jarrett TW, et al.: Protease inhibitorinduced urolithiasis. Urology 1997, 50:508–511.

    Article  PubMed  CAS  Google Scholar 

  70. Boubaker K, Sudre P, Bally F, et al.: Changes in renal function associated with indinavir. AIDS 1998, 12:F249–254.

    Article  PubMed  CAS  Google Scholar 

  71. Sarcletti M, Petter A, Romani N, et al.: Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000, 54:261–270.

    PubMed  CAS  Google Scholar 

  72. Gagnon RF, Tecimer SN, Watters AK, et al.: The Natural History of Leukocyturia Associated with Indinavir Treatment in HIV+ Individuals. Am J Nephrol 2000, 20:448–454.

    Article  PubMed  CAS  Google Scholar 

  73. Kopp JB, Falloon J, Filie A, et al.: Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002, 34:1122–1128. Indinavir is associated with two pyuria syndromes: interstitial nephritis and lower urinary tract inflammation. Both syndromes are generally associated with urinary multinucleated giant cells (histiocytes).

    Article  PubMed  CAS  Google Scholar 

  74. Tashima KT, Horowitz JD, Rosen S: Indinavir nephropathy [letter]. N Engl J Med 1997, 336:138–140.

    Article  PubMed  CAS  Google Scholar 

  75. Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al.: Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998, 13:750–753.

    Article  PubMed  CAS  Google Scholar 

  76. Vigano A, Rombola G, Barbiano di Belgioioso G, et al.: Subtle occurrence of indinavir-induced acute renal insufficiency [letter]. AIDS 1998, 12:954–955.

    PubMed  CAS  Google Scholar 

  77. Perazella MA, Kashgarian M, Cooney E: Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998, 50:194–196.

    PubMed  CAS  Google Scholar 

  78. Sarcletti M, Zangerle R: Persistent flank pain, low-grade fever, and malaise in a woman treated with indinavir. AIDS Patient Care STDs 1999, 13:81–87.

    Article  PubMed  CAS  Google Scholar 

  79. Grabe DW, Eisele G, Miller C, et al.: Indinavir-induced nephropathy. Clin Nephrol 1999, 51:181–183.

    PubMed  CAS  Google Scholar 

  80. Jaradat M, Phillips C, Yum MN, et al.: Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 2000, 35:E16.

    PubMed  CAS  Google Scholar 

  81. Hanabusa H, Tagami H, Hataya H: Renal atrophy associated with long-term treatment with indinavir [letter]. N Engl J Med 1999, 340:392–393.

    Article  PubMed  CAS  Google Scholar 

  82. Hamm M, Wawroschek F, Rathert P: Urinary cytology changes in protease inhibitor induced urolithiasis. J Urol 2000, 163:1249–1250.

    Article  PubMed  CAS  Google Scholar 

  83. Cattelan AM, Trevenzoli M, Naso A, et al.: Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000, 30:619–621.

    Article  PubMed  CAS  Google Scholar 

  84. Cattelan AM, Trevenzoli M, Sasset L, et al.: Indinavir and systemic hypertension. AIDS 2001, 15:805–807.

    Article  PubMed  CAS  Google Scholar 

  85. Engeler DS, John H, Rentsch KM, et al.: Nelfinavir urinary stones. J Urol 2002, 167:1384–1385.

    Article  PubMed  Google Scholar 

  86. Tanji N, Tanji K, Kambham N, et al.: Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001, 32:734–740.

    Article  PubMed  CAS  Google Scholar 

  87. Gow PJ, Pillay D, Mutimer D: Solid organ transplantation in patients with HIV infection. Transplantation 2001, 72:177–181.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kidney Disease Section, National Institutes of Health, Building 10, Room 3N114, 20892-1268, Bethesda, MD, USA

    Jeffrey B. Kopp MD

Authors
  1. Jeffrey B. Kopp MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopp, J.B. Renal dysfunction in HIV-1-infected patients. Curr Infect Dis Rep 4, 449–460 (2002). https://doi.org/10.1007/s11908-002-0013-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-002-0013-3

Keywords

Search

Navigation